Attached files
| file | filename |
|---|---|
| EX-10.5 - EX-10.5 - Thorne Healthtech, Inc. | d162335dex105.htm |
| EX-10.4 - EX-10.4 - Thorne Healthtech, Inc. | d162335dex104.htm |
| EX-5.1 - EX-5.1 - Thorne Healthtech, Inc. | d162335dex51.htm |
| EX-3.3 - EX-3.3 - Thorne Healthtech, Inc. | d162335dex33.htm |
| EX-3.2 - EX-3.2 - Thorne Healthtech, Inc. | d162335dex32.htm |
| S-1/A - S-1/A - Thorne Healthtech, Inc. | d162335ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Thorne HealthTech, Inc.
New York, New York
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated April 19, 2021, except for the disclosure regarding disaggregated revenues by sales channel within Note 2, as to which the date is June 4, 2021, and except for the effects of the stock split discussed in Note 21, as to which the date is September 13, 2021, relating to the consolidated financial statements of Thorne HealthTech, Inc., which is contained in that Prospectus.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
| /s/ BDO USA, LLP |
| Raleigh, North Carolina |
| September 13, 2021 |